Synthesis and Biological Evaluation of Novel 5,7-Diphenylimidazo1,2-apyridine Derivatives
文献类型：期刊论文
| 作者 | Liao Huimin; Chong Liane; Tan Li; Chen Xiaodan; You Rui; Gong Ping |
| 刊名 | CHEMICAL RESEARCH IN CHINESE UNIVERSITIES
 |
| 出版日期 | 2014 |
| 卷号 | 30期号:5页码:759-763 |
| 关键词 | AGENTS Imidazo1,2-apyridine Biological evaluation Antitumor activity |
| ISSN号 | 1005-9040 |
| 其他题名 | Synthesis and Biological Evaluation of Novel 5,7-Diphenylimidazo1,2-apyridine Derivatives |
| 英文摘要 | A series of novel 5,7-diphenylimidazo1,2-apyridine derivatives was designed and synthesized. The in vitro cytotoxic activities of all the target compounds against human colorectal cancer(HT-29), human lung cancer(H460), human gastric cancer(MKN45) and human breast cancer(MDA-MB-231) cell lines were evaluated. The pharmacological results indicated that most of the target compounds showed moderate to excellent activities against the tested cell lines. The most promising compound 4h(0.20, 0.006, 0.08, 0.021 mu mol/L) was 2.6, 5.1, 3.6 and 21.9 times more active than EPC2407(0.52, 0.031, 0.29, 0.46 mu mol/L) against HT-29, H460, MKN45 and MDA-MB-231 cell lines, respectively. |
| 资助项目 | [National Natural Science Foundation of China] |
| 语种 | 英语 |
| CSCD记录号 | CSCD:5259969 |
| 源URL | [http://ir.imr.ac.cn/handle/321006/156537]  |
| 专题 | 金属研究所_中国科学院金属研究所 |
| 作者单位 | 中国科学院金属研究所 |
| 推荐引用方式 GB/T 7714 | Liao Huimin,Chong Liane,Tan Li,et al. Synthesis and Biological Evaluation of Novel 5,7-Diphenylimidazo1,2-apyridine Derivatives[J]. CHEMICAL RESEARCH IN CHINESE UNIVERSITIES,2014,30(5):759-763. |
| APA | Liao Huimin,Chong Liane,Tan Li,Chen Xiaodan,You Rui,&Gong Ping.(2014).Synthesis and Biological Evaluation of Novel 5,7-Diphenylimidazo1,2-apyridine Derivatives.CHEMICAL RESEARCH IN CHINESE UNIVERSITIES,30(5),759-763. |
| MLA | Liao Huimin,et al."Synthesis and Biological Evaluation of Novel 5,7-Diphenylimidazo1,2-apyridine Derivatives".CHEMICAL RESEARCH IN CHINESE UNIVERSITIES 30.5(2014):759-763. |
入库方式： OAI收割
来源：金属研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。